Loading stock data…
$3.44-0.04 (-1.15%)
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
Neuphoria Therapeutics Inc. in the Healthcare sector is trading at $3.44 with a market capitalization of $25M. The stock is currently near its 52-week low of $3.19, remaining 17.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $15.00M↑ | $662,715 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$827,284↑ | -$2.35M↑ | -$5.65M↓ | $11.97M↑ | -$3.40M |
| Net Income | -$505,063↓ | $1.86M↑ | -$9.91M↓ | $11.26M↑ | -$1.94M |
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a ...